Publikation
Strategies to manage hepatitis C virus (HCV) disease burden
Wissenschaftlicher Artikel/Review - 01.05.2014
Kautz A, Myers R P, Nemecek V, Øvrehus A L H, Parkes J, Peltekian K M, Ramji A, Razavi H, Reis N, Roberts S K, Mullhaupt B, Moreno C, Mendes Correa M C, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marinho R T, Marotta P, Mauss S, Roudot-Thoraval F, Ryder S D, Vandijck D, Vogel W, Waked I, Weis N, Wiegand J, Yosry A, Zekry A, Negro F, Sievert W, van Thiel I, Van Damme P, Urbanek P, Sarmento-Castro R, Sarrazin C, Semela David, Sherman M, Shiha G E, Sperl J, Stärkel P, Stauber R E, Thompson A J, Gower E, Kaita K D E, Wedemeyer H, Bihl F, Bilodeau M, Blasco A J, Brandão Mello C E, Bruggmann P, Calinas F, Calleja J L, Cheinquer H, Christensen P B, Berg T, Balık I, Aleman S, Duberg A S, Buti M, Rosenberg W M, Frankova S, Esmat G, Örmeci N, Van Vlierberghe H, Gschwantler M, Akarca U, Clausen M, Coelho H S M, Gerstoft J, Giria J A, Gonçales F L, Guimarães Pessôa M, Hézode C, Hindman S J, Hofer H, Husa P, Idilman R, García-Samaniego J, Ferreira P R, Ferraz M L G, Cornberg M, Cramp M E, Dore G J, Doss W, El-Sayed M H, Ergör G, Estes C, Falconer K, Félix J, Kåberg M
Bereiche
PubMed
DOI
Zitation
Art
Zeitschrift
Veröffentlichungsdatum
eISSN (Online)
Seiten
Kurzbeschreibung/Zielsetzung
The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.